INDIGO Trial Context: Vorasidenib and Early Treatment in IDH-Mutant Glioma

Advances in molecular profiling have significantly reshaped the understanding of glioma biology, particularly in tumors driven by IDH mutations. Beyond their role in tumor formation and progression, these mutations are increasingly recognized for their contribution to tumor-associated epilepsy, creating new opportunities for therapies that may address both oncologic and neurologic disease burden simultaneously.

In this Special Report, Ugur T. Sener, MD, consultant in the Section of Neuro-Oncology and chair of the Division of Neuro-Oncology at Mayo Clinic, discusses the mechanistic rationale behind targeting mutant IDH in low-grade glioma. Framed around emerging data with vorasidenib, the conversation explores how disruption of the oncometabolite 2-hydroxyglutarate may influence both glioma biology and seizure generation in affected patients.

In this episode, Sener walks through the biologic role of IDH mutations, the downstream production of 2-hydroxyglutarate, and the ways in which this metabolite contributes to both tumor development and epilepsy. He also explains how vorasidenib’s dual inhibition of mutant IDH1 and IDH2 may provide a targeted strategy capable of addressing both processes at the same time.